Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Thursday 07 May, 2009

Summit Corporation PLC

Disposal of zebrafish business

Summit Corporation plc
("Summit plc" or "the Company")


Oxford, UK, 7 May 2009 - Summit Corporation plc (AIM: SUMM), the UK
drug discovery company, announces that it has divested its zebrafish
services business unit to Evotec AG (Frankfurt Stock Exchange: EVT;

The key terms of the divestment are as follows:

*    For £500,000 in cash, Evotec has acquired the assets and
  operations associated with the zebrafish business currently located
  in Oxfordshire, UK and Singapore;
*    Employees and costs associated with the zebrafish business will
  be transferred to Evotec with immediate effect

Summit remains in discussion with a number of parties regarding
certain current programmes and obligations in order to realise cash
and reduce expenditure and to secure the future of the Company.
 Further announcements will be made as appropriate.

The Board remains confident of Summit's ability to develop value in
the medium and longer-term.  The Company will continue to focus on
the discovery and development of products from its proprietary
iminosugar drug discovery platform.

The proceeds from this divestment will support Summit's on-going
operational costs and working capital requirements.  The net book
value of tangible assets transferred is £187,000 and had a net
operating profit of £27,000 for the financial year 2007/08.

Steven Lee, PhD, Chief Executive Officer at Summit said, "This
transaction is positive news both for Summit and the zebrafish
services business.  Evotec offers the zebrafish business, including
its staff, an exciting future.

"Importantly, the deal provides immediate financial support to Summit
that will assist our on-going efforts towards securing the future of
the business.  This will focus on our iminosugar drug discovery
platform, an area of science in which Summit has an unparalleled
expertise, and offers great potential for the discovery of new

For further information please contact:

Summit Corporation PLC
Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations

Tel: +44 (0)1235 443951

Panmure Gordon (Nominated adviser and Broker)
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)

Tel: +44 (0)207 459 3600
                               - END -

About Summit plc
Summit plc is a UK based drug discovery company with a major focus on
developing new therapeutics from its iminosugar drug discovery

Summit believes iminosugars are the key to gaining access to several
disease mechanisms where classical drugs have had little success, and
thus offer a major opportunity for the discovery and development of
new medicines.

Carbohydrates (sugars) play critical roles in maintaining correct
functioning of many normal processes in healthy individuals and
errors in carbohydrate recognition or modification can lead to
malfunction in cells resulting in disease.  Iminosugars have the
potential to mimic carbohydrates or to interact with processes which
manipulate carbohydrates to modify activity or to correct aberrant
function.  Additionally, iminosugars, due to their sugar-like
properties, have important effects when interacting with many other
unexploited therapeutic targets.

Summit is at the forefront of developing new iminosugar drug
candidates with a focus in two therapeutics areas: anti-infectives
and metabolic diseases.

Commercially, Summit has a track record of signing programme
agreements and currently has an out-licensed product portfolio
comprising of four drug programmes with BioMarin, Orient Europharma,
Evolva and the Lilly TB Drug Discovery Initiative.  In the future
these programmes may generate success based milestone payments and
royalties for Summit.

In addition, Summit owns Dextra Laboratories, a business unit that
operates independently to Summit, which offers specialist
carbohydrate chemistry services to third parties on a fee-for-service
or collaborative basis.

The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at

About Evotec AG
Evotec is a leader in the discovery and development of novel small
molecule drugs. The Company has built substantial drug discovery
expertise and an industrialized platform that can drive new
innovative small molecule compounds into the clinic. In addition,
Evotec has built a deep internal knowledge base in the treatment of
diseases related to neuroscience, pain, and inflammation. Leveraging
these skills and expertise the Company intends to develop
best-in-class differentiated therapeutics and deliver superior
science-driven discovery alliances with pharmaceutical and
biotechnology companies.

Evotec has long-term discovery alliances including Boehringer
Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. The
Company's has a P2X7 antagonist for the treatment of inflammatory
diseases in clinical development and a series of preclinical
compounds and development partnerships, including a strategic
alliance with Roche for EVT 101, a subtype selective NMDA receptor
antagonist, for the treatment of depression.

This document contains "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as
"anticipates", "intends", "plans", "seeks", "believes", "estimates",
"expects" and similar references to future periods, or by the
inclusion of forecasts or projections.
Forward-looking statements are based on the Company's current
expectations and assumptions regarding our business, the economy and
other future conditions. Because forward-looking statements relate to
the future, by their nature, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult
to predict. The Company's actual results may differ materially from
those contemplated by the forward-looking statements. The Company
cautions you therefore that you should not rely on any of these
forward-looking statements as statements of historical fact or as
guarantees or assurances of future performance. Important factors
that could cause actual results to differ materially from those in
the forward-looking statements and regional, national, global
political, economic, business, competitive, market and regulatory


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


a d v e r t i s e m e n t